Core findings. The study curates 238 Pseudomonas Llps (106 LlpA, 132 LlpB), builds a maximum-likelihood phylogeny separating them from L-type pyocins and from Burkholderia/Xanthomonas clades, and screens all 238 against 101 genome-sequenced Pseudomonas isolates (23,406 scored observations). Of 148 confidently active Llps, 99 preferred short BamA loop 6, 19 long loop 6, and 30 were broad targeters, mapping loop 6 as the dominant susceptibility determinant .
Validation and statistics. A purified-protein overlay assay (21 Llps × 10 isolates, three replicates, ICC = 0.91) largely recapitulated screen-defined preferences (PI concordance Spearman ρ = +0.74, P = 0.0006) . Partial Mantel tests showed loop 7 carries no susceptibility signal independent of loop 6 (r = 0.03, P = 0.51), while loop 6 retains correlation (r = 0.38, P < 0.001) .
Structural mechanism. A 2.66 Å cryo-EM structure of BAM64825–LlpA-C16 (PDB 26HD) reveals loop 6 engaged exclusively by the N-terminal β-lectin domain — a fundamentally different interface from the inter-domain cleft used by L-type pyocins — while the C-terminal peptide β-pairs with invariant BamA β-strand 1 via main-chain hydrogen bonds . This directly explains how single-lectin LlpBs retain BamA targeting and why the C-terminal β-lectin domain was lost independently twice. Twelve of 17 AlphaFold3 models recapitulated C-terminal peptide deployment to β-strand 1, supporting a conserved [Ω/Φ]-x-[Ω/Φ]-x-[Ω/H] mimicry motif despite 152 distinct peptides across 246 Llp C-termini — convergent β-signal mimicry analogous to darobactin . The register-shifted dimer-state structure suggests stepwise peptide deployment, though the authors correctly caution it was captured in a non-physiological BAM dimer.
Strengths and limitations. Strengths: genus-scale sampling, orthogonal assay validation, honest reporting of screen noise, deposited structures/data/code. Limitations: the binary colony screen is noisy (71% concordance, κ = 0.50); only one experimental Llp–BAM complex was solved, so the generality of the N-terminal-face binding mode rests partly on AlphaFold3 models that were themselves filtered by the experimental structure; LlpB O-antigen engagement and potency effects of domain loss remain unresolved; escape-mutation fitness costs are untested. Evidence distinguishing binding vs inhibition is solid; engineering claims are prospective, not demonstrated.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.